secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alto Neuroscience, Inc. (ANRO)
CIK:        0001999480
Form:       8-K
Filed at:   2026-05-13T11:04:01+00:00
Accession:  0001999480-26-000011
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alto Neuroscience Q1 net loss $26.2M; initiates Phase 2b trial for ALTO-207 in TRD
--------------------------------------------------------------------------------

- Net loss of $26.2M for Q1 2026 vs $15.2M in Q1 2025; R&D expenses rose to $20.3M.
- Cash and equivalents of $264.2M as of March 31, 2026, up from $177.0M after $120M PIPE closed in March.
- Phase 2b trial of ALTO-207 in treatment-resistant depression (TRD) initiated; topline data expected 2H 2027.
- ALTO-101 Phase 2 POC trial missed primary endpoint (theta-ITC) but showed significant EEG biomarker effects and attention improvement.
- ALTO-300 and ALTO-100 Phase 2b topline data readouts delayed to 1H 2027 and mid-2027, respectively, due to enhanced patient eligibility review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/0001999480-26-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1999480/000199948026000011/alto-20260513.htm
  HTML page:      https://secwatch.observer/filing/0001999480-26-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer